Back to top
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Image: Bigstock
AstraZeneca (AZN) Shows Strength: Stock Moves 9.2% Higher
AstraZeneca PLC (AZN - Free Report) was a big mover last session, as the company saw its shares rise a little above 9% on the day. The upside was driven after the company’s qannouncement of extremely encouraging results in a phase 3 trial by its candidate drugs. Also, this led to far more shares changing hands than in a normal session. This continues the recent uptrend for the company as the stock is now up nearly 13% in the past one-month time frame.
The company has seen three positive estimate revisions in the past 30 days, while its Zacks Consensus Estimate moved higher over the same timeframe. So make sure to keep an eye on this stock going forward to see if this recent jump can turn into more strength down the road.
AstraZeneca currently carries a Zacks Rank #3 (Hold).
Astrazeneca PLC Price
Astrazeneca PLC Price | Astrazeneca PLC Quote
A top-ranked stock in the Large Cap Pharmaceuticals industry is Sanofi (SNY - Free Report) holding a Zacks Rank #2 (Buy). You can the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Is AZN going up? Or down? Predict to see what others think: Up or Down
5 Trades Could Profit "Big-League" from Trump Policies
If the stocks above spark your interest, wait until you look into companies primed to make substantial gains from Washington's changing course.
Today Zacks reveals 5 tickers that could benefit from new trends like streamlined drug approvals, tariffs, lower taxes, higher interest rates, and spending surges in defense and infrastructure. See these buy recommendations now >>